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Abstract
Background: Epithelial ovarian cancer (EOC) constitutes more than 90% of ovarian cancers and is associated with high
mortality. EOC comprises a heterogeneous group of tumours, and the causes and molecular pathology are essentially
unknown. Improved insight into the molecular characteristics of the different subgroups of EOC is urgently needed, and
should eventually lead to earlier diagnosis as well as more individualized and effective treatments. Previously, we reported a
limited number of mRNAs strongly upregulated in human osteosarcomas and other malignancies, and six were selected to
be tested for a possible association with three subgroups of ovarian carcinomas and clinical parameters.
Methodology/Principal Findings: The six selected mRNAs were quantified by RT-qPCR in biopsies from eleven poorly
differentiated serous carcinomas (PDSC, stage III–IV), twelve moderately differentiated serous carcinomas (MDSC, stage III–
IV) and eight clear cell carcinomas (CCC, stage I–IV) of the ovary. Superficial scrapings from six normal ovaries (SNO), as well
as biopsies from three normal ovaries (BNO) and three benign ovarian cysts (BBOC) were analyzed for comparison. The gene
expression level was related to the histological and clinical parameters of human ovarian carcinoma samples. One of the
mRNAs, DNA polymerase delta 2 small subunit (POLD2), was increased in average 2.5- to almost 20-fold in MDSC and PDSC,
respectively, paralleling the degree of dedifferentiation and concordant with a poor prognosis. Except for POLD2, the serous
carcinomas showed a similar transcription profile, being clearly different from CCC. Another mRNA, Killer-specific secretory
protein of 37 kDa (KSP37) showed six- to eight-fold higher levels in CCC stage I compared with the more advanced staged
carcinomas, and correlated positively with an improved clinical outcome.
Conclusions/Significance: We have identified two biomarkers which are markedly upregulated in two subgroups of ovarian
carcinomas and are also associated with stage and outcome. The results suggest that POLD2 and KSP37 might be potential
prognostic biomarkers.
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Introduction
In Norway and the United States, ovarian cancer is the fourth
and fifth most frequent cause of cancer death in women,
respectively [1,2]. At the time of diagnosis, almost 70% of the
patients have distant spread of disease (stage III–IV), and their 5-
year relative survival rate is only about 30% [1,2]. The cause(s)
and mode of progression are poorly understood, and the patients
are treated similarly in spite of tumour heterogeneity [3–6].
EOC comprises several subtypes of histopathologically different
tumours [7]. There is growing evidence for the existence of at least
two distinct tumourigenetic pathways, corresponding to the devel-
opment of type I and type II tumours [3,6,8–10]. Type I tumours
include highly differentiated serous carcinomas, mucinous carcino-
mas, endometroid carcinomas, clear cell carcinomas and malignant
Brenner tumours. They are thought to arise from precursor lesions
such as cystadenomas, borderline tumours or endometriosis and
suggested to be a result of mutations in e.g. KRAS, BRAF, CTNNB1
or PTEN genes [4,6,8,9]. Type II carcinomas include moderately
and poorly differentiated serous carcinomas, carcinosarcomas and
undifferentiated carcinomas, and appear to originate de novo from as
yet no known identified precursor lesions, possibly resulting from
mutations in e.g. TP53 [4,6,8,9,11]. Thus, ovarian carcinogenesis
appears to be associated with abnormalities in multiple gene families.
How these genetic alterations are reflected in changes in transcrip-
tional activity and carcinogenesis are not understood.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13837Previously, we reported a limited number of mRNAs strongly
upregulated in human osteosarcomas and several other malignan-
cies [12]. Further analyses on various types of human malignant
cell lines and normal tissues showed that six mRNAs were highly
expressed: KSP37, C9orf89, PRAT4A, NOLA2, ANT2 and POLD2
(Table 1). Apart from C9orf89 and PRAT4A (unknown at project
start), these mRNAs code for proteins known to be associated with
malignancy [13–16]. We hypothesized that these mRNAs might as
well be associated with ovarian cancer. In the present study, we
quantified these mRNAs by RT-qPCR in biopsies from eleven
PDSC (stage III–IV), twelve MDSC (stage III–IV) and eight CCC
(stage I–IV) as well as control tissue representing six SNO, three
BNO and three BBOC. The expression levels were related to
histological, clinical and laboratory parameters. We found that two
of the mRNAs were markedly upregulated in two subgroups of
ovarian carcinomas and also associated with stage and outcome.
Results
Mean expression levels of six selected mRNAs in three
subgroups of ovarian carcinomas compared with three
different control groups
Expression levels of the six selected mRNAs in PDSC, MDSC
and CCC are presented in Figures 1,2,3. Figure 1 shows heat-
maps of log10 transformed p-values (t-test) comparing the mean
expression levels as DCq (delta quantification cycles) values in
PDSC, MDSC and CCC with SNO, BNO and BBOC. P-values
less than 0.05 were used as cut-off value for significance. When
comparing PDSC with SNO and BBOC, respectively, the
following mRNAs were significantly differentially expressed:
PRAT4A (p=8.1610
25 and 2.6610
23), NOLA2 (p=1.3610
24
and 3.5610
23), ANT2 (p=6.3610
25 and 2.6610
23) and POLD2
(p=3.4610
28 and 2.4610
25), whereas comparing these carcino-
mas with BNO, ANT2 (p=1.9610
22) and POLD2 (p=3.1610
22)
showed a differential expression. For MDSC, POLD2
(p=9.1610
24) showed differential transcription when compared
with SNO. NOLA2 (p=1.1610
22) and POLD2 (p=4.3610
22)
were differentially expressed when CCC were compared with
BNO. These significantly differentially expressed mRNAs were all
upregulated in PDSC and MDSC, while downregulated in CCC
(data not shown). Thus, several of the six previously shown
upregulated mRNAs in osteosarcomas were also differentially
expressed in the ovarian carcinomas. Furthermore, the overall
transcriptional activity of these genes was similar when comparing
BBOC with SNO and BNO, while PRAT4A and POLD2 showed
significant differential expression (p,0.05) when BNO and SNO
were compared (data not shown).
Individual expression levels of six selected mRNAs in
three subgroups of ovarian carcinomas compared with
SNO controls
Figure 2 shows mRNA expression profiles of all 31 carcinomas
employing SNO as a control group, depicted as heat-maps of
normalized log2 transformed original fold change (FC) values.
Higher mRNA levels were detected in PDSC and MDSC for
PRAT4A, NOLA2, ANT2 and POLD2. PRAT4A, NOLA2 and ANT2
showed a similar mRNA expression in PDSC and MDSC in
contrast to POLD2, being clearly more upregulated in PDSC
compared with MDSC. The mRNA levels were reduced for
KSP37 and C9orf89 in both PDSC and MDSC. Furthermore,
except for C9orf89, a distinct mRNA expression pattern of the
mRNAs was present in CCC. The heat-maps looked almost
identical when BBOC were used as the control group, but differed
slightly when BNO were used (Figure S1).
Mean expression levels of six selected mRNAs in three
subgroups of ovarian carcinomas compared with SNO
controls
Figure 3 shows bar plots of mean mRNA expression (loge
transformed original FC values) in PDSC, MDSC and different
stages of CCC, using SNO for comparison. In PDSC, POLD2 was
almost 20-fold upregulated (FC 19.4), whereas C9orf89, PRAT4A,
NOLA2 and ANT2 were only moderately upregulated (FC 1.2–3.1)
and KSP37 slightly downregulated (FC 0.7). In MDSC, transcrip-
tion levels of KSP37 and C9orf89 were reduced (FC 0.5 and 0.7
respectively), while the other mRNAs showed moderate upregula-
tions (FC 1.8–2.5). In CCC stage I, KSP37 was markedly
upregulated (FC 4.3), but downregulated in the more advanced
stages of CCC (FC 0.5). In both stage I and stages II–IV of CCC,
PRAT4A, ANT2 and POLD2 were slightly upregulated (FC 1.4–
1.7), whereas C9orf89 and NOLA2 were slightly downregulated (FC
0.6–0.96). Thus, when comparing KSP37 expression levels in CCC
stage I with the more advanced stages of CCC, MDSC and
PDSC, a six- to eight-fold difference was detected. Further
analyses of the FC values in Figure 3 are shown in Table 2. The
mean mRNA profiles were almost identical when BBOC were
used as control tissue, but differed more when BNO were used
(Figure S2).
The mean mRNA expressions, given as loge transformed
original FC values, in the different ovarian carcinoma subgroups
were also compared (t-test). P-values less than 0.001 were used as
cut-off value for significance. POLD2 mRNA levels were
significantly higher in PDSC compared with both MDSC (FC
19.4 vs. 2.5; p=1.7610
28) and CCC (FC 19.4 vs. 1.5;
p=5.6610
28), whereas transcription levels of NOLA2 and ANT2
Table 1. Title and assumed function of six selected mRNAs [12].
Title Assumed function
Killer-specific secretory protein of 37 kDa; KSP37 Cytotoxic lymphocyte-mediated immunity [13]
Chromosome 9 open reading frame 89; C9orf89 CARD binding region* [29]
Protein associated with TLR4,A; PRAT4A TLR4 associated* [30]
Nucleolar protein family A, member 2; NOLA2 Associated with telomerase and snoRNPs [14]
Adenine nucleotide translocator 2; ANT2 ADP/ATP exchange [15]
DNA polymerase delta 2 small subunit; POLD2 DNA replication and repair [16]
*Unknown at project start. CARD: Caspase Recruitment Domain. TLR: Toll-like receptor. SnoRNPs: small nucleolar ribonucleoproteins. KSP37 is synonymous with
fibroblast growth factor binding protein 2; FGFBP2 (www.ncbi.nlm.nih.gov/genebank).
doi:10.1371/journal.pone.0013837.t001
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vs. 0.8; p=3.0610
26 and FC 3.1 vs. 1.5; p=5.7610
24,
respectively). The results were similar irrespectively of the control
tissue used (data not shown).
Correlation of mRNA expression to clinical, laboratory
and histological parameters
In a single-factor linear regression model, normalized FC values
of the six mRNAs, employing SNO as controls, were correlated
with clinical, laboratory and histological parameters. The
parameters shown in Table S1 as well as histological subgroups
were included in the regression analysis. The significant positive
correlations (p,0.05) between mRNA expression levels and these
parameters are shown in Table 3. Only KSP37 was significantly
associated with several clinical parameters, being positively
associated with favourable prognostic factors such as localized
disease, long progression-free survival (.18 months) and long
overall survival (.36 months). Furthermore, it was negatively
associated with unfavourable prognostic factors such as more
advanced disease, short progression-free survival and short overall
survival (data not shown). When correlating the FC values with
histological subgroups, KSP37 expression was positively associated
with CCC, whereas PRAT4A, NOLA2 and POLD2 were positively
associated with PDSC. The transcriptional levels of C9orf89 and
ANT2 did not correlate with any of the parameters.
Discussion
A major finding in this study was the strong upregulation of
POLD2 in PDSC compared to control tissues and other
histological subgroups of ovarian carcinomas examined. POLD2
is a subunit of the DNA polymerase delta complex, encoding a
protein involved in DNA replication and repair [16]. It is
downregulated by the PTEN tumour suppressor gene [17],
already known to be involved in ovarian carcinogenesis
[4,6,8,9]. In gliomas, a consistent pattern of chromosomal
Figure 1. Mean differential expression levels of six selected mRNAs (horizontal) in three subgroups of ovarian carcinomas
compared with three different control tissues (vertical). Log10 p-values of the T-test of delta Cq values are shown as heat-maps, where the
smaller the p-value, the brighter the blue colour (scale bar). P,0.05 represents significant differential expression. SNO: superficial scrapings from
normal ovaries. BBOC: biopsies from benign ovarian cysts. BNO: biopsies from normal ovaries.
doi:10.1371/journal.pone.0013837.g001
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seven ‘‘landscape genes’’ associated with patient survival, among
these POLD2 [18].
KSP37 mRNA levels were clearly and distinctly regulated in
early stage of CCC, another histological subgroup of ovarian
cancer. KSP37 is identified as FGFBP2, a member of the fibroblast
growth factor binding protein 2 family (www.ncbi.nlm.nih.gov/
genebank). It is expressed in cytotoxic T lymphocytes and natural
killer cells, and is suggested to have a ‘‘cytotoxic potential’’ which
so far has not been identified [13]. Yamanaka et al. found that a
high KSP37 expression in high-grade gliomas was positively
correlated with survival. Furthermore, KSP37 was more closely
correlated with survival than histological grade [19], while in the
present study, a positive correlation with histological type, clinical
stage as well as good prognosis was observed.
A challenge related to the understanding of molecular portraits of
ovarian cancer has been the lack of representative control tissue.
Histologically, EOC is thought to originate from the single layer of
ovarian surface epithelium (OSE) [5,7,20–22], which therefore
should be the most representative control tissue. Because the OSE
represents only a small fraction of the total ovary, the availability of
OSE RNA is limited. Zorn et al [23] compared the gene expression
profiles of OSE brushings, whole ovary samples, cultures of normal
OSE and immortalized OSE cell lines. The transcriptional profiles
were markedly distinct, but it was concluded that OSE brushings
were most representative as control material, since it is not exposed
to in vitro manipulations and does not contain stromal components.
In the present study, OSE, as represented by six superficial
scrapings from normal ovaries (SNO) was used as reference
material. Furthermore, three biopsies from normal ovaries (BNO)
and three biopsies from benign ovarian cysts (BBOC) were included
for additional comparisons. Ourresults showedthat the investigated
six mRNAs were similarly expressed in SNO and BBOC, but
differed more in BNO (data not shown). Furthermore, the mRNA
levels of the carcinomas were similar both when compared to SNO
and BBOC, but different when compared to BNO (Figures 1,2,3
and Figure S1, S2). Apparently, SNO and BBOC showed
comparable transcriptional activity for these six mRNAs. The
findings are not unexpected, since the benign ovarian cysts used for
control tissue are believed to originate from OSE, whereas BNO
mainlyconsistofstromaltissue [7].Thus, forstudypurposes,benign
cysts originating from OSE, being simpler to obtain than OSE, and
superficial scrapings of normal ovaries appear to be alternative
choices as control tissue for EOC.
Except for the marked upregulation of POLD2 in PDSC, the
expression levels of the other mRNAs in PDSC and MDSC were
similar, in agreement with a common tumourigenetic pathway for
moderately and poorly differentiated serous carcinomas as previously
suggested [10]. Thus, the fact that POLD2 mRNA expression
paralleled the dedifferentiation of MDSC to PDSC, increasing from
2.5-fold in MDSC to almost 20-fold in PDSC, underscores the
uniqueness of this transcript. Since patients with PDSC generally
have a worse clinical outcome than patients with MDSC, the
significantly higher POLD2 expression in PDSC compared with
MDSC could have a bearing on a poor prognosis, possibly through a
replication advantage in cells overexpressing POLD2.
The marked upregulation of KSP37 confined to CCC stage I, as
well as its positive association with clinical variables of good
prognosis, suggest also a possible predictive role of this transcript.
Even though these results are very much in concordance with
overall results from studies on other malignancies, the present
results are novel related to ovarian carcinomas and need to be
confirmed. The different transcriptional profiles for clear cell
carcinomas and serous carcinomas are in agreement with distinct
Figure 2. Differential expression levels of six selected mRNAs
(vertical) in 31 individual tissue samples (horizontal) of three
subgroups of ovarian carcinomas compared with superficial
scrapings from normal ovaries. Normalized log2 transformed
original FC values (Z-scores) are shown as heat-maps, where the
higher/lower the FC value, the brighter the red/green colour,
respectively (scale bar). Black colour illustrates no difference in FC
values of cancer tissue and control tissue.
doi:10.1371/journal.pone.0013837.g002
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with other studies [24,25]. Although the present study is based on
a limited patient cohort of only three subgroups of ovarian
carcinomas, the strong association of two of the mRNAs with
histology, stage and outcome suggest that they may have potential
as cancer markers.
Materials and Methods
Patients and tissue material
The study was approved by the Regional Committee of Medical
and Health Research Ethics (REK) in Eastern Norway and all
participating women signed informed consent. Tissue specimens as
well as clinical and laboratory information were obtained from
women primarily operated for gynecological tumours at Oslo
University Hospital, Ulleval, in the period 2003 to 2008. All tissue
samples were snap-frozen in liquid nitrogen, except SNO, which
were transferred to 500 ml TRIzol solution (Invitrogen.com)
immediately after harvesting in order to avoid mRNA degrada-
tion. The samples were stored in a biobank at 280uC until
processed.
The expression of the six selected mRNAs was studied in a total
of 31 epithelial ovarian carcinomas and twelve benign samples.
The carcinomas included twelve MDSC (stage III–IV), eleven
PDSC (stage III–IV) and eight CCC (stage I–IV). Six SNO, three
BNO and three BBOC were used for comparison. SNO were
taken from the surface of normal ovaries by scraping the ovaries
with a scalpel, as cervical pap smear brushings yielded too little
material (data not shown). By this method, the vast majority of
harvested cells were immunologically verified as epithelial (data
not shown). The three benign cysts were cystadenofibromas,
containing both epithelial and stromal cells. BNO consisted almost
exclusively of stromal cells as confirmed by histology. In
accordance with the literature [23], we used OSE, represented
by SNO, as reference material. The histological diagnoses of all
samples were confirmed by an experienced pathologist.
Clinical and laboratory information was collected from hospital
records and additional preoperative patient interviews, shown in
Table S1. All patients and controls were of Western European
descent, postmenopausal (apart from two being perimenopausal)
and had no diseases influencing survival other than the ovarian
cancer. All patients but four (two with MDSC and two with
PDSC) were primarily operated by at least a total hysterectomy or
a uterus amputation, a bilateral salpingo-oophorectomy and an
omentectomy. No patients received neoadjuvant chemotherapy,
whereas all patients but three (one in each histological group)
received adjuvant chemotherapy. The effect of treatment was
evaluated by clinical examinations and serum CA125 measure-
ments at minimum.
Selected mRNAs
Six mRNAs were selected from a subtraction cDNA library of
human osteosarcoma [12]. They represented interesting candi-
date genes, being strongly upregulated in several osteosarcoma
and other malignant human cell lines, and showed a differential
expression between human cancers and normal tissues. Except
for C9orf89 and PRAT4A, whose identities and functions were
unknown at project start, these mRNAs code for proteins
possibly associated with malignancies. The titles and assumed
protein functions of the selected candidate mRNAs are shown in
Table 1.
Primer sequences
PCR primers (Table S2) were designed by using the Invitrogen
database and tested for homology with other sequences at the
Figure 3. Mean expression levels of six selected mRNAs in moderately and poorly differentiated serous carcinomas (stage III–IV)
and clear cell carcinomas (stage I and II–IV) compared with superficial scrapings from normal ovaries. Loge transformed original FC
values with standard deviation are shown as bar plots.
doi:10.1371/journal.pone.0013837.g003
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intron spanning to avoid co-amplification of genomic DNA.
RNA isolation
Tissue specimens were either crushed frozen or homogenized
directly for 262 minutes in 750 ml TRIzol using a Tissuelyzer
(Qiagen.com). Total RNA was extracted using the TRIzol method
according to the manufacturer’s instructions. Isolated total RNA
was quantified (Nano Drop spectrophotometer, Saveen Werner
AB) and quality controlled by the RNA Nano 6000 assay on the
Bioanalyzer 2100 system (Agilent). RNA integrity number (RIN)
and 28S/18S ratios were calculated to ensure a satisfactory RNA
quality and integrity of the samples. To remove genomic DNA,
total RNA was treated using RNase-free DNase I (Roche.com).
Total RNA was further purified on RNeasy MinElute clean up
spin columns (Qiagen.com), eluted with RNase free water,
aliquoted and stored at 280uC until analyzed.
Quantitative reverse transcription-polymerase chain
reaction (RT-qPCR)
One mg of total RNA from each sample was reversely
transcribed using 2.5 U/ml Omniscript enzyme (Qiagen.com), 1
X RT-buffer, 1 mM dNTPs, 2.5 mM oligo-d(T)-primer and 1 U/
ml RNase inhibitor (final concentrations) in a total volume of 20 ml
for one hour at 37uC. For all samples, a negative RT-control
without Reverse Transcriptase enzyme was included. cDNA was
PCR-amplified with primers from the six specific mRNAs and two
endogenous reference genes (b-actin and GAPDH) in replicate sets
of two to six, with a coefficient of variation of less than 1.6 percent.
The samples were analyzed on a real-time fluorescence Light-
Cycler instrument (Roche.com) according to the manufacturer’s
instructions in a final volume of 20 ml using a LightCycler Fast
start SYBR Green kit. PCR conditions essentially contained 2 ml
cDNA, 25 mM MgCl2 and 0.5 mM of forward and reverse
primers. The following cycle conditions were used: 10 min
denaturation at 95uC before 45 cycles at 95uC for 0 s, 56uC for
10 s and 70uC for 5 s.
Gene expression patterns for the six selected mRNAs were
calculated using the comparative crossing threshold method of
relative quantification (DDCq method) [26], and presented as
relative (DCq) and fold change (FC) values. All expression levels
were normalized to the reference genes separately, giving overall
similar results. b-actin quantification was most linear over a wide
dilution range and preferred as reference gene. DCq was
designated as the mean quantification cycle of an mRNA in a
tissue subtracted with the mean quantification cycle of a reference
RNA in the same tissue. DDCq was calculated as mean DCq of
each of the three different control groups subtracted by DCq of
each cancer tissue sample (mean of replicates), whereas FC was
2
DDCq.
Table 3. Results of single-factor regression analysis.
KSP37 PRAT4A NOLA2 POLD2
Clinical parameters
FIGO stage I (all CCC) 7.9610
27
Progression-free survival $18 months 1.6610
22
Overall survival $36 months 3.3610
22
Status at last follow-up: Alive, no relapse of EOC 8.0610
25
Status at last follow-up: Alive, relapse of EOC 1.2610
22
Histological parameters
PDSC 1.8610
22 2.1610
23 1.2610
25
CCC 6.8610
23
CCC: Clear cell carcinomas. PDSC: Poorly differentiated serous carcinomas. EOC: Epithelial ovarian cancer. Significant positive correlations (p-values) between mRNA
expression levels and parameters are shown. Detailed explanation is given in Table 1 and Table S1.
doi:10.1371/journal.pone.0013837.t003
Table 2. Statistical analyses of the FC values shown in
Figure 3.
KSP37 C9orf89 PRAT4A NOLA2 ANT2 POLD2
PDSC,
stage III–IV
Average 0.70 1.17 2.77 3.03 3.12 19.42
Stdev 0.62 0.93 1.06 1.43 1.11 14.79
Min 0.07 0.50 1.24 1.36 1.51 5.90
Max 1.64 3.27 4.82 6.73 4.92 59.30
MDSC,
stage III–IV
Average 0.52 0.69 1.98 1.78 2.40 2.50
Stdev 0.39 0.46 1.15 1.42 2.36 1.13
Min 0.06 0.29 0.60 0.74 0.77 1.38
Max 1.42 1.79 3.97 6.06 9.42 4.66
CCC, stage I
Average 4.28 0.69 1.42 0.96 1.35 1.66
Stdev 3.11 0.46 1.32 0.50 0.28 1.54
Min 0.95 0.17 0.39 0.57 1.17 0.67
Max 8.40 1.29 3.34 1.68 1.77 3.94
CCC, stage II–IV
Average 0.49 0.64 1.38 0.73 1.60 1.43
Stdev 0.40 0.23 0.65 0.12 0.91 0.35
Min 0.12 0.36 0.90 0.56 0.82 1.11
Max 1.04 0.90 2.31 0.83 2.76 1.75
PDSC: Poorly differentiated serous carcinomas. MDSC: Moderately differentiated
serous carcinomas. CCC: Clear cell carcinomas. Stdev: Standard deviation. Min:
minimal value. Max: Maximal value. mRNA description is given in Table 1.
doi:10.1371/journal.pone.0013837.t002
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Mean DCq values of each histological subgroup of ovarian
carcinomas were compared to mean DCq values of each control
group by performing a two-tailed t-test, presented in heat-maps by
log10 transformed p-values (Figure 1). Log2 transformed original
FC values of each individual sample (n=31) were normalized (Z-
scores) and shown as heat-maps by applying a two-way clustering
method [27] (Figure 2 and Figure S1). Mean original FC values of
the three ovarian carcinoma subgroups were presented by loge
transformed bar plots (Figure 3 and Figure S2). Finally, a linear
regression model [28], testing the correlation of histological,
clinical and laboratory parameters with mRNA expression levels
given as normalized FC values, was used (Table 3).
Supporting Information
Figure S1 Differential expression levels of six selected mRNAs
(vertical) in 31 individual tissue samples (horizontal) of three
subgroups of ovarian carcinomas compared with biopsies from
benign ovarian cysts (a) and biopsies from normal ovaries (b).
Normalized log2 transformed original FC values (Z-scores) are
shown as heat-maps, where the higher/lower the FC value, the
brighter the red/green color, respectively (scale bar). Black color
illustrates no difference in FC values of cancer tissue and control
tissue.
Found at: doi:10.1371/journal.pone.0013837.s001 (1.92 MB TIF)
Figure S2 Mean expression levels of six selected mRNAs in
moderately and poorly differentiated serous carcinomas (stage III–
IV) and clear cell carcinomas (stage I and II–IV) compared with
biopsies from benign ovarian cysts (a) and biopsies from normal
ovaries (b). Loge transformed original FC values with standard
deviation are shown as bar plots.
Found at: doi:10.1371/journal.pone.0013837.s002 (2.74 MB
TIF)
Table S1 Clinical and laboratory information for patients
included.
Found at: doi:10.1371/journal.pone.0013837.s003 (0.05 MB
DOC)
Table S2 Primer sequences of six selected mRNAs.
Found at: doi:10.1371/journal.pone.0013837.s004 (0.04 MB
DOC)
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